Anti-angiogenic therapies, mostly targeting the VEGF/VEGFR signaling axis, are currently routinely used in the clinic to treat several advanced or metastatic cancers, including colon, kidney, liver and breast cancers [15, 16]. This evidence concerns the gene KDR and breast carcinoma.